Third, in the rapidly evolving treatment landscape of CLL, our study was limited to patients treated with CIT, a modality that has largely been superseded by BTK and BCL-2 inhibitors. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.